Try this. The deadline for abstract submission was in Feb 2016. The A2-73 trial data was not available then. Two poster presentations now planned by Dr M. Note the topics being A2-73 related and current(no restrictions on time there). Next, if the AAIC council judges that late breaking A2-73 results warrant a spot(see criteria) on the podium then it further validates the significance of results. Any PR/announcement on "late breaking" is expected over the next couple of days. This is a similar pattern to last years AAIC w/A2-73.
Developing Topic submissions are designed to bring the latest research findings in the field to AAIC attendees. Specifically, Developing Topic abstracts present research findings that were not available at the time of the general abstract submission deadline in February.
Note: AAIC 2016 Developing Topic abstracts will be considered for poster presentation only unless the research is considered to be late-breaking.
Late-breaking research/newness of information.
Potential impact on the research community.
Quality of scientific research.
Relevance to Alzheimer's disease and related disorders.
Topics of interest include basic and translational science, diagnosis and prognosis, therapeutics, and public health and psychosocial issues.
Previously submitted/reviewed abstracts will not be considered.
A limited number of abstracts are selected, with selection based on timeliness and scientific merit.
Only under extraordinary circumstances will abstracts without results be considered.
Accepted abstracts are published in an online supplement to the Association's journal, Alzheimer's & Dementia: The Journal of the Alzheimer's Association.
Developing Topic abstracts must be submitted via the online system.
Developing Topic abstracts are not accepted for the Alzheimer's Imaging Consortium or Technology and Dementia.
Developing Topic abstracts do not include the AAIC Featured Research Session format.
An individual may be the presenting author on one oral presentation (includes a featured research session) and two posters slotted on different days. Exception: An author may present in two oral platforms as long as one is a Developing Topic session.
Rules fro AAIC are in play, this is a tip(IMO)...wait for late breaking later this week according to AAIC protocol.
Does that say (mean)what I think it says(means)?
New Exploratory Alzheimer’s Drug Anavex 2-73: Dose Dependent Clinical Cognitive Improvement Observed in Mini Mental State Examination (MMSE) and Other Cognitive Markers in a Phase 2a Study in Mild-to-Moderate Alzheimer’s Patients
Metro Toronto Convention Centre Room: Hall D/E
9:30am - 10:30am
Sun, Jul 24
BUT....if it does happen WOW it will be massive, spectacular...whatever. Is he saying/suggesting something positive but is not at liberty to divulge? BTW, not long ago the same people were negative about A2-73 ever making it. Strange.
I did google...look for Anavex 8-k June 23 , selection from multiples...set of 20+ slides...good luck
Tried posting...no joy...looks like the real thing ....more than just money here
Agree, the whole multiple cycle thing we have been through over the past few months fits w/ the wringer process we have experienced.